WaveMan
WaveMan · Company
OTLC · Oncotelic Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

OTLC Oncotelic Therapeutics (OTLC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000908259
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about OTLC

Insiders, 180 days
+$38.5K net bought
2 buyers

Oncotelic Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Oncotelic Therapeutics, Inc. insiders bought a net $38.5K of stock across 25 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-07-02 SECtraded 2026-07-01
240,000
$10.3K
-52.8%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Jun 24, 2026.
  • +0.0% median (+13.7% mean) 90-day return after 23 previous buys.
  • The trade is 0.3% of the 94,124,319 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CHAIRMAN AND CEO Trieu Vuong bought about $10.3K of OTLC on Jul 1, 2026, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days.
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-06-24 SEC
115,000
$5.8K
-52.8%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 buys), the last on Jun 23, 2026.
  • +0.0% median (+16.6% mean) 90-day return after 22 previous buys.
  • The trade is 0.1% of the 93,884,319 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CHAIRMAN AND CEO Trieu Vuong bought about $5.8K of OTLC on Jun 24, 2026; 1 other insider bought within 30 days.
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-06-24 SECtraded 2026-06-23
75,000
$3.8K
-52.8%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 buys), the last on Jun 22, 2026.
  • +0.0% median (+19.3% mean) 90-day return after 21 previous buys.
  • The trade is 0.1% of the 93,769,319 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CHAIRMAN AND CEO Trieu Vuong bought about $3.8K of OTLC on Jun 23, 2026; 1 other insider bought within 30 days.
Trieu Vuong
CHAIRMAN AND CEO
BUY
2026-06-24 SECtraded 2026-06-22
65,000
$3.2K
-52.8%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Jun 17, 2026.
  • +16.7% median (+22.3% mean) 90-day return after 20 previous buys.
  • The trade is 0.1% of the 93,694,319 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CHAIRMAN AND CEO Trieu Vuong bought about $3.2K of OTLC on Jun 22, 2026; 1 other insider bought within 30 days.
Shah Amit B.
CFO
BUY
2026-06-22 SEC
20,000
$1.0K
-62.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 5.3% of the 378,837 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: CFO Shah Amit B. bought about $1.0K of OTLC on Jun 22, 2026; 1 other insider bought within 30 days.
25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 20 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$38.5K over 180 days
+$37.5K of it by a 10%+ holder
more than 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-96.0% year over year
below 90% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
the lowest in Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch OTLC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-79.0%12M
-79%-45%-12%+22%2025-102025-122026-022026-042026-062026-082026-10 2026-07-01 · Trieu Vuong bought $10.3K2026-06-17 · Trieu Vuong bought $9.6K2026-06-24 · Trieu Vuong bought $5.8K2026-06-15 · Trieu Vuong bought $4.8K2026-06-23 · Trieu Vuong bought $3.8K2026-06-22 · Trieu Vuong bought $3.2K2026-06-22 · Shah Amit B. bought $1.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OTLC: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in OTLC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OTLC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $38.5K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OTLC financials

Revenue growth
-96.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.02x
long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.33x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end)
Return on equity
+181.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+117.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-3.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$12.8M
market value at close 2026-10-27 on 2026-08-13 shares, plus long-term 2026-06-30 plus current 2025-06-30 (12 months older than the period end), minus cash 2025-09-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$70.0Kn/a
Operating income-$3.2M-$3.6M-$6.6M-$9.7M
Net income$249.3M-$4.5M-$7.9M$5.1M
EPS (diluted)0.59-0.01-0.020.01
Operating cash flow-$1.4M-$740.3K-$1.3M-$1.5M
Cashn/a$86.1K$170.4K$241.5K
Long-term debt$1.7Mn/a$1.9Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

OTLC Stock Sonar score 5/7 axes

Find similar shapesCompare

OTLC ranks highest on profitability (93rd percentile) and insider conviction (76th), and lowest on growth (10th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersRisk
Profitability
93
Inputs
  • Return on equity+181.4% · 98 pct, sector of 545
  • Return on assets+117.5% · 98 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-3.0% · 83 pct, sector of 576
Financial health
67
Inputs
  • Debt to equity0.02x · 73 pct, sector of 352
  • Cash flow to debt-0.33x · 62 pct, sector of 371
Growth
10
Inputs
  • Revenue growth, YoY-96.0% · 10 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$38K · 71 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Risk and compliance
54
Inputs
  • Short interest, % of float+0.0% · 97 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+24.6% · 11 pct, sector of 511
2 not measured: Institutional and government, US patents
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

OTLC filings, in plain words

Are Oncotelic Therapeutics insiders buying or selling OTLC?

In the 180 days to 2026-10-28, Oncotelic Therapeutics insiders were net buyers, a net $38.5K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Oncotelic Therapeutics insiders were net buyers of OTLC, a net $38.5K across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $37.5K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies